Table 1.
Current Immunotherapy Trials in HNSCC Targeting the Immunosuppressive Tumor Microenvironment
| Targets | Treatments | Phase | Clinical Trial ID | Patient Eligibility |
|---|---|---|---|---|
| IDO1 | GDC-0919 | I | NCT02048709 | Recurrent/refractory solid tumors |
| IDO1 PD-1 |
Epacadostat + Nivolumab |
I/II | NCT02327078 | Recurrent/metastatic solid tumors including HNSCC |
| IDO1 PD-1 |
INCB024360 (Epacadostat) + MK-3475 (Pembrolizumab) |
I/II | NCT02178722 | Recurrent/metastatic solid tumors including HNSCC |
| IDO1 JAK1 |
INCB024360 (Epacadostat) + INCB039110 |
Ib | NCT02559492 | Advanced/metastatic solid tumors including HNSCC |
| PD-L1 STAT3 CXCR2 |
MEDI4736 + AZD9150 or AZD5069 |
Ib/II | NCT02499328 | Recurrent/metastatic HNSCC |
| PDE5 | Tadalafil | II | NCT01697800 | Untreated nonmetastatic HNSCC |
| PDE5 Tumor Mucin 1 (MUC1) |
Tadalafil Anti-MUC1 Vaccine |
I/II | NCT02544880 | Resectable HNSCC |
| CSF1R PD-1 |
PLX3397 + MK-3475 (Pembrolizumab) |
I/IIa | NCT02452424 | Recurrent/metastatic solid tumors including HNSCC |
| CSF1R PD-1 |
FPA008 +/− Nivolumab |
Ia/Ib | NCT02526017 | Advanced solid tumors including HNSCC |
| CCR4 PD-L1 CTLA-4 |
KW-0761 (Mogamulizumab) + MEDI4736 or Tremelimumab |
I | NCT02301130 | Advanced solid tumors including HNSCC |
| CCR4 PD-1 |
KW-0761 (Mogamulizumab) + Nivolumab |
I | NCT02705105 | Advanced/metastatic solid tumors |
| CCR4 4-1BB |
KW-0761 (Mogamulizumab) + PF-05082566 |
Ib | NCT02444793 | Advanced/metastatic solid tumors |
| CCR4 | KW-0761 (Mogamulizumab) |
I/II | NCT02281409 | Advanced/metastatic solid tumors |
| OX40 4-1BB |
PF-04518600 +/− PF-05082566 |
I | NCT02315066 | Advanced/metastatic solid tumors including HNSCC |
| OX40 | MEDI6469 | Ib | NCT02274155 | Resectable HNSCC |
| GITR | TRX518 | I | NCT01239134 | Advanced/metastatic melanoma or solid tumors |
| GITR | TRX518 | I | NCT02628574 | Advanced solid tumors |
| GITR | MEDI1873 | I | NCT02583165 | Advanced solid tumors |